Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Istradefylline Phase 3 in Parkinson's Disease
NCT01968031Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Oct 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of Istradefylline in Parkinson's disease (PD) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at 12 weeks. Started Oct 2013; status: completed.
02
Drugs
Istradefylline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01968031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968031.